See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
DHTV
Popular
Top Rated

Related Community Videos on Diabetes Health TV

Diabetes Health Magazine - The Story of How It All Began

Publisher Nadia Al-Samarrie tells her story

Diabetes Health Magazine - The Story of How It All Began

Diabetes Friendly Desserts for Special Occasions

Kevin Coyne

Diabetes Friendly Desserts for Special Occasions

Doctor's Choice® - Advanced Wound Care - Bandages and Dressings Designed for Diabetes Patients

Alan E. Nash, CEO Scivolutions

Doctor's Choice® - Advanced Wound Care - Bandages and Dressings Designed for Diabetes Patients

Novo Nordisk Archives

Novo Nordisk

Page 3
Novo Says Early Use of Victoza Aids Type 2 Control

News from Danish pharmaceutical manufacturer Novo Nordisk reinforces the growing trend toward using a two-drug combination in the early treatment of type 2 diabetes. (See "A Conversation About Janumet and Earlier Combination Therapy Type 2 Diabetes" for more discussion about the phenomenon.)

Comments 2 comments - Dec 15, 2011 - * * * * *

Novo Nordisk Files for FDA Approval of New Insulin

A brand new insulin will soon be on pharmacy shelves in the United States if Danish pharmaceutical company Novo Nordisk has its way. The company has filed for approval from the Food and Drug Administration to sell insulin degludec, an original formulation that lasts an extra-long time. Insulin degludec is injected only once a day. Once under the skin, the dose of insulin is absorbed slowly and consistently, allowing for better nighttime control, according to Novo. Most importantly, test subjects had a low rate of hypoglycemia on the drug.

Comments 2 comments - Oct 15, 2011 - * * * * *

Novo Says Early Use of Victoza Aids Type 2 Control

News from Danish pharmaceutical manufacturer Novo Nordisk reinforces the growing trend toward using a two-drug combination in the early treatment of type 2 diabetes. (See "A Conversation About Janumet and Earlier Combination Therapy for Type 2 Diabetes" for more discussion about this phenomenon.) In a study it released in Lisbon, Portugal, at the recent meeting of the European Association for the Study of Diabetes, Novo said that combining its recently released drug Victoza® (liraglutide) with another drug early in therapy helps recently diagnosed type 2s achieve greater blood glucose control than they can with a single drug.

Comments 0 comments - Oct 2, 2011 - * * * * *

Do What You Love, and It Will Never Be Work

Being a rookie driver on the fast-paced IndyCar racing circuit is pressure enough for any 26-year-old. But for Charlie Kimball, one of four wheel men on businessman Chip Ganassi's IndyCar race team, there's the added need to manage type 1 diabetes while roaring around the track at speeds that often exceed 200 miles per hour.

Comments 0 comments - Sep 25, 2011 - * * * * *

The State of Insulin Injection

What's Being Researched Now

Comments 4 comments - Sep 11, 2011 - * * * * *

Type 2 Drug Victoza Helps Type 1s, Too

Victoza, a drug aimed at type 2 diabetes, may turn out to be a boon for type 1 diabetes patients as well. A small clinical study shows that patients with well-controlled type 1 who took Victoza daily for just one week experienced a 15 percent drop in their blood sugar levels. Patients who took the drug over a full 24-week test period needed less and less insulin, decreasing their average mealtime dose by seven units and their all-day insulin requirement by eight.

Comments 2 comments - Jul 11, 2011 - * * * * *

Sanofi Says Late-Stage Trial of Type 2 Drug a Success

French drug maker Sanofi-aventis says that results from a Phase III trial of its experimental type 2 diabetes drug lixisenatide show that the drug successfully lowered patients' blood glucose levels and body weight, but did not increase the risk of hypoglycemia.

Comments 0 comments - May 23, 2011 - * * * * *

Albertson’s Supermarket Chain Joins Diabetes Alliance

Albertson's LLC, a nationwide supermarket chain with more than 200 stores, has announced that it will participate in the Diabetes Control Program (DCP) of the Diabetes Prevention and Control Alliance. The DCP works through trained pharmacists to provide education and support to people with diabetes.

Comments 0 comments - May 7, 2011 - * * * * *

Novo Nordisk Joins Nationwide Diabetes/Pre-Diabetes Treatment Alliance

Novo Nordisk, the world's largest insulin manufacturer, has joined the Diabetes Prevention and Control Alliance (DPCA), a group whose goals are to reduce people's risk of developing diabetes and to work with people who already have it.

Comments 1 comment - Mar 4, 2011 - * * * * *

Insulin Needle Wins Design Prize, But You Can't Buy It in the States

The Chicago Athenaeum: Museum of Architecture has announced its 60th annual Good Design Awards, which honor "quality design of the highest form, function, and aesthetic." Guess which paragon of contemporary design won an award this year? An insulin needle. Called the NovoTwist and made by Novo Nordisk for use with insulin pens, this marvel of design has a bayonet fitting that allows "just twist" attachment and detachment to compatible pens, and an audible and tactile "click" that confirms attachment of the needle.

Comments 4 comments - Feb 1, 2011 - * * * * *

Next Page » « Previous Page
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.